Quibim Precision

QUIBIM_Symbiosis of Radiology and AI

QUIBIM at RSNA 2018!

We are happy to announce that QUIBIM will be attending this year’s annual meeting of the Radiological Society of North America – RSNA 2018. From November 25 to 29, many of our Quibimers will be in Chicago demoing, sharing and showing our Radiomic solution for Hospitals and Radiology departments.

This year, QUIBIM developments are focused on the Symbiosis of Radiology and Artificial Intelligence to seamlessly integrate imaging biomarkers into radiology workflows.

QUIBIM_RSNA BOOTH 7367G

Attendees can find us at the Machine Learning Showcase – Booth #7367G  (North Building Level 3), where anyone is welcome to come over and explore the latest version of our QUIBIM Precision® Platform for medical images processing and imaging biomarkers analysis.

WANT TO DISCOVER OUR PLATFORM?

demo

image2

QUIBIM will be also taking part in the Machine Learning Showcase through a communication from our CEO and Founder, Ángel Alberich-Bayarri, on November 25 at 12:30 pm. The communication is entitled “QUIBIM Precision 3.0: AI as a Means, Not an End, for Imaging Biomarkers Integration in Clinical Practice” and shares QUIBIM insights about the role of AI on imaging biomarkers integration.

RSNA 2018_AAB_QUIBIM

Furthermore, as members of the NVIDIA Inception Program, QUIBIM will be demoing at the NVIDIA booth #6568 on November 26 at 10:00 am. Don’t miss it!

nvidia banner

It is a great opportunity for QUIBIM to be engaged in such a recognised event and get in touch with professionals in the fields of radiology and medical imaging.

MEET US!

Presentation of QUIBIM Precision platform at PARENCHIMA meeting in Prague, October 2018

QUIBIM continua su liderazgo en imagen médica e inteligencia artificial gestionando los datos y los algoritmos de un proyecto europeo en 25 países

QUIBIM ha sido seleccionado como el socio principal para gestionar todos los datos de imagen médica y los algoritmos de análisis de la iniciativa PARENCHIMA, un proyecto europeo de la acción COST (European Cooperation in Science and Technology) que se inició en abril de 2017 con el objetivo de impulsar el uso de biomarcadores de imagen calculados con resonancia magnética para mejorar el manejo de pacientes con enfermedad renal crónica. Multiples Investigadores científicos de 25 países europeos, líderes en imagen médica y enfermedad renal, utilizarán en esta iniciativa la plataforma QUIBIM Precision® para la realización de análisis avanzados. Uno de los desafíos del proyecto es centralizar los datos de imágenes médicas y los algoritmos de todos los socios para permitir la comparación entre protocolos de adquisición y algoritmos computacionales en términos de calidad y precisión. El resultado del proyecto consistirá en dos nuevos estándares para la adquisición y análisis de imágenes de resonancia magnética en la enfermedad renal crónica.

En la pasada reunión anual en Praga, los días 4 y 5 de octubre, se formalizó el acuerdo entre los socios del consorcio PARENCHIMA y QUIBIM. La plataforma QUIBIM Precision fue seleccionada como el mejor sistema para la gestión de las imágenes y de integración de los nuevos algoritmos de análisis.

Steven Sourbron, profesor de resonancia magnética en la Universidad de Leeds y coordinador del proyecto, manifestó: “Estoy encantado de que QUIBIM haya elegido asociarse con PARENCHIMA para ayudarnos a mejorar los resultados en beneficio de los pacientes, al hacer accesibles estas innovadoras y prometedoras técnicas para su uso en ensayos clínicos y manejo asistencial del paciente”. Frank Zöllner, profesor adjunto de física médica en la Universidad de Heidelberg y líder del grupo de trabajo encargado de la base de datos y el software de PARENCHIMA, comentói que “QUIBIM tiene una gran experiencia en algoritmos de inteligencia artificial y gestión de datos de imagen médica y estamos seguros de que son el colaborador adecuado que necesita este proyecto”. Angel Alberich-Bayarri, CEO de QUIBIM expresó que “QUIBIM está orgulloso de ser parte de este proyecto donde se generarán nuevos estándares de adquisición y análisis de imágenes en la enfermedad renal crónica, un escenario clínico no abordado previamente de forma conjunta. El impacto de este estudio será global y mejorará la vida de millones de pacientes, ya que esta enfermedad afecta al 10% de la población mundial.”

 

Acerca de PARENCHIMA

Hoy en día, los biomarcadores de resonancia magnética renal están infrautilizados no sólo en la investigación, pero también en la práctica clínica, principalmente debido a la falta de difusión y a la necesidad de desarrollo de técnicas propias. Transferir soluciones a otros centros donde funcionen y estén validadas es, por lo tanto, un reto todavía no resuelto, lo que conlleva una replicación significativa de esfuerzos, una falta de estandarización en los métodos y dificultades para comparar los resultados entre los centros. Esto también limita la comercialización y dificulta la creación de ensayos multicéntricos y la traslación a la práctica clínica.

El objetivo general de PARENCHIMA es eliminar las principales barreras para un estudio clínico más extenso y la consiguiente explotación comercial de los biomarcadores de resonancia magnética renal.

PARENCHIMA coordinará la investigación de los principales grupos europeos en esta área para:

  • mejorar la reproducibilidad y estandarización de los biomarcadores de resonancia magnética renal;
  • aumentar su disponibilidad desarrollando un conjunto de herramientas de acceso abierto con herramientas software y datos;
  • demostrar la validez biológica y la utilidad clínica en un estudio clínico prospectivo multicéntrico.

Para aumentar el impacto de este proyecto, hemos decidido unir nuestros esfuerzos. Más información en: www.renalmri.org

 

Sobre QUIBIM

QUIBIM es una empresa de Valencia (España) que aplica inteligencia artificial y modelos computacionales avanzados a las imágenes radiológicas para medir de manera objetiva los cambios producidos por una lesión o por los tratamientos farmacológico, y ofrece información cuantitativa adicional al enfoque cualitativo de la radiología. La tecnología y los servicios de QUIBIM se aplican en la práctica clínica, los ensayos clínicos, la formación en radiología y los proyectos de investigación. Más información en: www.quibim.com

Presentation of QUIBIM Precision platform at PARENCHIMA meeting in Prague, October 2018

QUIBIM to manage imaging data and AI for European project PARENCHIMA across 25 countries

QUIBIM has been selected as the main partner to manage all imaging data and analysis algorithms of the PARENCHIMA initiative, a COST action project initiated in April 2017 with the objective of boosting the use of renal MRI biomarkers to improve the management of chronic kidney disease patients. The leading scientific researchers in medical imaging of the kidney from 25 European countries will be using QUIBIM Precision® platform for highly advanced image analysis. One of the challenges of the project is to centralize the medical imaging data and algorithms from all partners to allow for acquisition protocols and algorithms comparison in terms of quality and precision. The outcome of the project will consist of two new standards for image acquisition and analysis in MR of the kidney.

In the past annual meeting of the consortium in Prague, which took place on 4-5 October, an agreement was established between QUIBIM and PARENCHIMA consortium partners for the selection of QUIBIM Precision platform as the best system for images management and integration of new analysis algorithms.

Steven Sourbron, Lecturer in Magnetic Resonance Imaging at the University of Leeds and project coordinator, expressed “I am delighted that QUIBIM has chosen to partner with PARENCHIMA, helping us to improve outcomes for patients by opening up these promising new methods for use in clinical trials and patient management”. Frank Zöllner, adjunct Professor for medical physics at the University of Heidelberg and leader of working group for PARENCHIMA database and software said “QUIBIM has strong expertise in AI algorithms and managing data and we are confident that they are the right collaborator for this project”. Angel Alberich-Bayarri, CEO of QUIBIM said that ”QUIBIM is excited to be part of this project, which will lead to new standards of image acquisition and analysis in Chronic Kidney Disease (CKD), an unaddressed clinical scenario. I am confident that the impact of this study will be global and improve lives of millions of patients, since it is a disease affecting 10% of population worldwide”

 

About PARENCHIMA

Renal MRI biomarkers are today underused in research and in clinical practice due to the need for dedicated in-house expertise and development. Transferring solutions to other centres is therefore a challenge, and this leads to a significant duplication of efforts, a lack of standardisation in the methods, and difficulties in comparing results between centres. This also limits commercial exploitation, and hinders the set-up of multi-centre trials or translation into clinical practice.

The overall aim of PARENCHIMA is to eliminate the main barriers to the broader study, commercial exploitation and clinical use of renal MRI biomarkers.

PARENCHIMA will coordinate the research of leading European groups in this area to:

  • improve the reproducibility and standardisation of renal MRI biomarkers;
  • increase their availability by developing an open-access toolbox with software and data;
  • demonstrate biological validity and clinical utility in a prospective multicentre clinical study.

In order to increase the impact of this project we are reaching out to join the efforts. More info at: www.renalmri.org

 

About QUIBIM

QUIBIM is a company from Valencia (Spain) which applies artificial intelligence and advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology. QUIBIM technology and services are applied in clinical practice, clinical trials, radiology education and research projects. More info at: www.quibim.com

QUIBIM_chest_xray_classifier_logo3

New Chest X-Ray Classification Tool

Despite the technological evolution of imaging modalities like CT, US and MRI, conventional X-ray remains the most performed examination in radiology departments, and remains a fundamental tool for anatomical analysis in the detection and diagnosis of respiratory diseases and bone tissue alterations. However, radiology departments have limitations in reporting the X-Rays due to the limited resources available (link).

QUIBIM has developed a Chest X-Ray Classification Tool that offers a solution to this problem which can help radiology departments become even more efficient. This classifier developed in collaboration with Hospital Universitario y Politécnico La Fe, estimates the probability of chest X-Rays of having a pathology using Artificial Intelligence.

How does it work?

This tool makes use of fourteen Convolutional Neural Networks trained with a database of more than 100,000 images (NIH ChestXray14 dataset) to estimate the probability of presence of the following pathologies in chest X-Rays: atelectasis, cardiomegaly, effusion, infiltration, mass, nodule, pneumonia, pneumothorax, consolidation, edema, emphysema, fibrosis, pleural thickening and hernia. Afterwards, the probabilities are used by a Fully Connected Neural Network to get the final probability of the X-Ray of being abnormal.

XRAY chest

Because of this AI methodology the classifier understands the visual patterns that are most indicative of the different pathologies using the knowledge extracted from the large dataset of radiographs used to train the networks. QUIBIM’s Chest X-Ray Classification Tool is able to learn further using new images, which means that this system is continually improving and evolving with time.

 What information does it provide?

Once all the quantifications are performed this tool provides an intuitive Structured Report with the patient’s information, the abnormal probability of the radiographs analyzed and the representation of the findings. In addition, if the image is classified as abnormal, the report shows the three pathologies that are more likely to be found and a heatmap that highlights the most abnormal regions. This report is designed to be very user friendly, to assist the user in understanding the tool’s findings at a glance in order to make its usage highly efficient.

Why is this new tool so useful?

Using this technology it is possible to prioritize unreported, potentially pathological radiographs which allows radiologists to focus their efforts on studies that are more likely to have pathologies and thereby become more efficient. This tool essentially ensures that pathological findings, which could have been unreported due to the heavy workload of radiology departments, are correctly reported.

QUIBIM’s goal is to provide the radiology departments with an optimal solution for automatic reading of X-Rays without interfering in the  workflow of the department.

QUIBIM’S Chest X-Ray Analysis Tool is already available at QUIBIM Precision® Depending on the needs of the department, this tool is accessible through the cloud with just a few clicks  or  it can be fully integrated in the radiology department’s workflow as a local solution for  seamless interpretation of  chest X-Rays.

boton try quibim

QUIBIM se posiciona en el mercado americano analizando hábitats tumorales y enfermedades difusas hepáticas

Ha cerrado acuerdos con la compañía EnvoyAI y ha abierto oficina en Silicon Valley

QUIBIM sigue creciendo en el desarrollo de algoritmos de análisis de imágenes médicas basados en modelos biológicos y en inteligencia artificial. La compañía, que cerró el año 2017 con un crecimiento del 500% en sus métricas de negocio (número de análisis y facturación), ha avanzado con la expansión al mercado americano de sus algoritmos para cáncer y enfermedades difusas hepáticas. Entre los hitos más relevantes, además de la reciente apertura de oficina en Palo Alto (Silicon Valley, California), QUIBIM ha establecido una alianza con la empresa EnvoyAI, dedicada a la integración y distribución de algoritmos de inteligencia artificial para imágenes médicas. EnvoyAI fue adquirida el año 2016 por TeraRecon, empresa con un software de visualización radiológica que se encuentra actualmente instalado en el 85% de los hospitales de Estados Unidos.

Estos algoritmos de QUIBIM para el mercado americano, ahora mismo en proceso de certificación por la Food and Drug Administration (FDA), caracterizan tanto las diferentes subregiones o habitats internos de un tumor como analizan por biopsia virtual hepática las enfermedades difusas tipo esteatosis, sobrecarga de hierro, inflamación y fibrosis.

En el ámbito de la oncología, QUIBIM proporciona una metodología que extrae datos de textura, celularidad y proliferación vascular en los tumores, siendo aplicable en lesiones cerebrales, de mama, próstata, hígado y recto, entre los principales tumores sólidos. Esta metodología puede aplicarse a las imágenes de Resonancia Magnética y Tomografía Computarizada, proporcionando una información pronóstica sobre la evolución de los pacientes y su respuesta a los diferentes tratamientos.

En el ámbito de las enfermedades difusas hepáticas, QUIBIM proporciona un algoritmo para realizar una biopsia virtual hepática, sin dañar al paciente, a partir de las imágenes de Resonancia Magnética y extrayendo la proporción de grasa, concentración de hierro y proporciones de inflamación y fibrosis hepática. Este análisis es de especial relevancia para el estudio y seguimiento de la esteatohepatitis y la hemocromatosis, y en la evaluación de la historia natural y su modificación por el tratamiento en las hepatopatías crónicas y la cirrosis. Actualmente esta información se obtiene a partir de biopsias convencionales, lo que implica un riesgo para el paciente y un sesgo inherente al procedimiento dado que sólo se obtiene información del lugar de la punción, mientras que el algoritmo de QUIBIM permite obtener información de todo el hígado de manera segura.

En palabras de su CEO, el Dr. Ángel Alberich-Bayarri, resumiendo estos hitos “estamos en una fase muy intensa de la compañía y con un crecimiento significativo, y gracias al esfuerzo del equipo hemos podido acelerar varios hitos que teníamos previstos en fases más tardías, como por ejemplo la alianza con EnvoyAI, la solicitud a FDA y la apertura de oficina en EEUU. Los algoritmos que hemos seleccionado para este mercado aportan un valor diferencial que ya hemos podido verificar, recibiendo solicitudes desde algunos hospitales antes de iniciar acciones comerciales.”

QUIBIM es una empresa biotecnológica nacida en Valencia y está especializada en la extracción de información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear, mediante técnicas originales y avanzadas de procesamiento computacional. Estos parámetros extraídos reciben el nombre de Biomarcadores de Imagen y aportan rasgos extraídos de las imágenes médicas, relacionadas con procesos biológicos normales, enfermedades o respuestas terapéuticas.

Además, el equipo ha desarrollado la plataforma QUIBIM Precision® de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía, TAC, Resonancia Magnética o PET, QUIBIM es capaz de aplicar algoritmos avanzados de análisis con metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de QUIBIM permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos. La compañía fue seleccionada en 2017 para el programa SME Instrument Fase II de la Comisión Europea.

QUIBIM Imaging Biomarkers made transparent

QUIBIM, AI imaging disruption to showcase the value of Precision

We are in the era of Precision Medicine, and so is Radiology. Nowadays, main imaging modalities like X-ray, computed tomography (CT), magnetic resonance (MR), positron emission tomography (PET) and hybrid machines, among others, have become measurement instruments. Images are not only pictures anymore, but thanks to the application of computational analysis and artificial intelligence, they are data, as you can learn in this excellent manuscript in Radiology.

Nowadays, when radiologists perform measurements of different organs, tissues and lesion properties using a workstation, they are used to get a number (i.e. lesion volume or perfusion). If they take the same images and they get to analyze them in a workstation from another vendor (not straightforward), it is pretty sure that they will obtain different results. This issue has introduced a sense of lack of standardization and homogenization in the quantitative medical imaging field.

I like to say that value is to trust in the product, and we have decided to be the first company in the world to open the validation process and tests results of our imaging biomarkers. Every time we buy a measurement device for daily life purposes (i.e. thermometer) we know the degree of uncertainty, why wouldn’t we do the same in AI algorithms and quantitative imaging?

We are proud to make this announcement at ECR 2018: Now it is possible to see the precision, accuracy and clinical evaluation results of our imaging biomarkers. We provide the precision (through Coefficient of Variation, CoV) and accuracy (through relative error, e) values through the publication of QUIBIM Technical Datasheets that you can find in the resources section of our webpage.

With this strategy QUIBIM is going a step further by being the first multi-vendor, web-based and real precision Medicine company of the medical imaging & AI market.

Concerned by the accuracy of your measurements? Let’s work together.

025-FEDER2-declaracion14-20

El proyecto QUIBIM recibe la ayuda del IVACE-PREPARACIÓN DE PROPUESTAS PARA CONVOCATORIAS H2020

QUIBIM es un proyecto empresarial de alto impacto social y sanitario, que extrae información cuantitativa de las imágenes médicas radiológicas, mediante técnicas innovadoras y avanzadas de procesado computacional, con el objetivo de mejorar los procesos de diagnóstico de enfermedades con alta incidencia y evaluar adecuadamente los cambios que producen los tratamientos farmacológicos en el organismo.

Durante 2016 el proyecto de internacionalización QUIBIM ha recibido la ayuda IVACE – PREPARACIÓN DE PROPUESTA PARA CONVOCATORIAS DEL PROGRAMA MARCO  H2020 DE INVESTIGACIÓN E INNOVACIÓN 2014-2020  (IMAPEA/2016/38) con el apoyo del Fondo Europeo de Desarrollo Regional (FEDER) con el objetivo de presentar nuestros servicios de diagnóstico y análisis avanzado de imagen médica y dar a conocer nuestra plataforma de análisis QUIBIM Precision® para el análisis de Biomarcadores de Imagen.

IVACE_QUIBIM

QUIBIM_MIUC

MIUC
the new toolkit of QUIBIM Precision® platform to beat traditional workstations

Quibim has implemented a new toolkit named MIUC (Medical Imaging Universal Connector) to close the gap between hospital IT systems and the Cloud. Whereas the Cloud satisfies the processing requirements, Quibim Precision® handle the functionalities related to communications and management of DICOM objects among the hospitals and radiological centers.

Quibim Precision® allows users in hospitals and radiology departments to have a seamless integration of imaging biomarkers analysis within the radiological workflow, due to the MIUC capabilities combined by the Quibim Precision® Cloud computing environment and the interoperability features implemented in our system. Both image upload and data retrieval are fully automated and users only need to access the PACS when they are notified that a new biomarker report is available.

MIUC is placed inside the hospitals and clinics and it is responsible to establish all the required communications between the PACS and Quibim Precision®. During the analysis of imaging biomarkers, the study is anonymized, sent to the Cloud and analyzed. The final result is a one-page report which is sent back to the MIUC or can be directly visualized in the Quibim Precision® web interface. Furthermore, in clinical environments, the report is converted into DICOM objects and stored in the PACS as a new series within the original study. To identify the original study, the MIUC implements backward traceability in the client side to reidentify the anonymized studies.

Our platform is intended to be used by radiologists, either from a clinical environment, thanks to the MIUC, or as a final user using the web interface. In the clinical environment scenario, radiologists using Quibim Precision® do not have to worry about where the study or the report is. Instead, these issues are transparent to the user, who do not have to perform any action to launch a biomarker process, given that the MIUC rule engine does such work for them. The user will be notified by email when a new biomarker report is ready (and available in both the PACS and the Quibim Precision® web interface).

Nowadays, our Quibim Precision® platform is compliant with the DICOM standard at both communication level and data management and formatting level. Specifically, our platform receives imaging studies from hospitals, radiological centers or pharma companies. Then, the system analyzes the study and obtains quantitative measures, which are stored in a quantitative database and structured in a one-page report on a per-patient basis. Finally, this report is returned back as a result.  Quibim Precision® allows annotating biomarker reports using terms from RadLex and MeSH, enhancing the interoperability of its biomarker reports with other health information systems. In fact, the imaging platform is seamlessly integrated with the hospital PACS, being able to query and retrieve medical studies, processing them and storing the resulting biomarker reports as DICOM objects in the hospital PACS. On the other hand, the processing stage is performed on the Cloud, taking advantage of its benefits: high-performance computing and real-time hardware scalability on demand.

But, what has changed?

In previous updates of our platform, we improved the performance, capabilities and user settings view. With this new suite software QUIBIM Precision®- MIUC does query/retrieve the PACS, anonymizes the PACS responses and forwards them to Quibim Precision® in the Cloud. Furthermore, the MIUC leads our solution to a higher level of automation, given that it monitors the PACS querying for incoming studies. Once a new study reaches the PACS, the MIUC analyzes its header and determines whether a new biomarker analysis must be launched or not, depending on some DICOM elements in the study like imaging modalities, study description, series description or body part among others. For each biomarker analysis available in Quibim Precision®, there is a predefined set of rules that establishes which studies are susceptible to be processed by each analysis method. An incoming study matches a given analysis method whenever it fulfils the predefined set of rules for such analysis method. When this happens, the MIUC automatically sends the study to the Quibim Precision® Cloud processing platform, where it will be processed by the matching biomarker analysis pipeline. Once processed, a biomarker report is generated with the results and sent back to the MIUC. Finally, the MIUC stores the report in the PACS as a DICOM object, making the report available for the specialist who requested it. This way, the Cloud platform remains centralized and, at the same time, fully integrated with the hospital IT systems.

With the arrival of MIUC toolkit the need for conventional workstations with expensive licenses in radiology departments completely disappears. As in other business areas that are evolving from product to service, the Quibim image analysis technology was designed to be offered as the service that puts disruptive image analysis solutions at your fingertips.

025-FEDER2-declaracion14-20

El proyecto QUIBIM recibe el apoyo del FONDO EUROPEO DE DESARROLLO FEDER

QUIBIM es un proyecto empresarial de alto impacto social y sanitario, que extrae información cuantitativa de las imágenes médicas radiológicas, mediante técnicas innovadoras y avanzadas de procesado computacional, con el objetivo de mejorar los procesos de diagnóstico de enfermedades con alta incidencia y evaluar adecuadamente los cambios que producen los tratamientos farmacológicos en el organismo.

Durante 2016 el proyecto de internacionalización QUIBIM ha recibido la ayuda IVACE (ITAPIN IT16 PLANES DE INTERNACIONALIZACIÓN PYME CV 2016) con el apoyo del Fondo Europeo de Desarrollo Regional (FEDER) con el objetivo de presentar nuestros servicios de diagnóstico y análisis avanzado de imagen médica y dar a conocer nuestra plataforma de análisis QUIBIM Precision® para el análisis de Biomarcadores de Imagen.

quibim map

SMEInstrument

QUIBIM granted with the H2020 – SME Instrument Phase II

QUIBIM team is proud to announce that the beneficiaries of the European Commission SME Instrument Phase 2 have been recently published, and our project has been awarded in the Open Disruptive Innovation (ODI) topic.

QUIBIM’s project “QUIBIM Precision” has been granted with 1.25M€ for the scaling and development of the company business plan through our cloud platform QUIBIM Precision®. This funding will boost and accelerate the strategic plan of the company, bringing new disruptive solutions to our platform, including dedicated High Performance Computing resources for our Machine Learning processes, incorporating new visual analytics tools and helping validate new imaging biomarkers that have been recently developed.

QUIBIM Precision® is an innovative imaging biomarker analysis platform in the cloud allowing for:

  1. Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and reproducibility.
  2. Medically certified: QUIBIM is medically valid to scientifically support decision making.
  3. Open to any physicians: Optimized User Interface (UI), user experience (UX) and imaging analysis functionalities.
  4. Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis.

Our technology based on machine learning and image processing algorithms scouts the image and compares it to similar images in our database with known ground-truth diagnosis, based on patterns not obvious to a human eye.

About QUIBIM
QUIBIM is a biotechnology company dedicated to advanced medical image analysis. It was one of the start-ups selected in the 3rd edition of the acceleration program “LANZADERA” and it’s a spin-off company of the Medical Research Institute Hospital La Fe. Recently the company closed an investment round to boost its growth, including Tech Transfer UPV, AYCE Capital, and BioInfoGate, as well as some company promoters . QUIBIM’s business model is based on the extraction of quantitative information from radiological and nuclear medicine imaging using original and advanced computational processing techniques.

In 2016, QUIBIM was also selected as one of the disruptive companies by the EU and granted with the first round of Horizon 2020 SME Instrument Phase I Program 2016 under the call: “SMEInst-01- 2016-2017: Open Disruptive Innovation Scheme”

SME instrument – Horizon 2020 call
The SME Instrument is divided into 3 phases covering different stages of the innovation cycle. Phase 1 aims to cover the assessment of technical feasibility and market potential of new ideas. The project will be supported by an investment of 50,000€ and the typical duration should be no longer than 6 months.

Phase 2 aims to cover R&D activities with a particular focus on demonstration activities (testing, prototype, scale-up studies, design, piloting innovative processes, products and services, validation, performance verification etc.) and market replication encouraging the involvement of end users or potential clients. Project funding should amount to no more than 2,500,000€ and the typical duration of this phase should range from 12 to 24 months.